Stockreport

The Female Health Company / Veru Healthcare Announces Successful Stage 1 of the Clinical Trial to Evaluate Bioequivalence Between Tamsulosin DRS and FLOMAX®

FEMALE HEALTH  (FHCO) 
US:NASDAQ Investor Relations: verupharma.com/investors
PDF --Stage 1 of Clinical Trial Completed; A Tamsulosin DRS Formulation is Selected That Demonstrates Profile Similar to FLOMAX® and May Provide Other Potential Advantages, [Read more]